HitGen Ltd recently announced that it has entered into a drug discovery research collaboration with Genentech, a member of the Roche Group, to identify potential small molecule leads against targets of interest to Genentech
Genevac, an SP Scientific brand, recently provided a leading pharmaceutical company with a glovebox-enclosed version of its EZ-2 centrifugal evaporator to safely remove solvents from cytotoxic drug preparations.
Synbal, Inc., a biotechnology company developing non-viral, cell-based gene therapy candidates for rare diseases, cancer, autoimmune and degenerative diseases, has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute
Tiziana Life Sciences plc (“Tiziana” or the “Company”), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, previously announced that it had submitted an Investigational New Drug (IND) application on 1 June 2018 to the U.S. Food and Drug Administration (FDA)
Strategic Acquisition Gives Company Ownership of Brand Name Drug and Related Market Authorizations in 22 Countries in Which Metastron™ is Already Registered and Approved for Sale
A technique to get more information from the blood of cancer patients than previously possible has been developed
Researchers from North Carolina State University have created the largest publicly available virtual library of macrolide scaffolds. The library – called V1M – contains chemical structures and computed properties for 1 million macrolide scaffolds with potential for use as antibiotics or cancer drugs
A UCLA-led team of scientists has developed a new technique that will enable researchers to easily and quickly determine the structures of organic molecules using very small samples
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate the combination of Aileron’s ALRN-6924 and Pfizer’s palbociclib, also known as IBRANCE®, in MDM2-amplified cancers.
Cyclica (www.cyclicarx.com), a Bayer G4A company is pleased to announce a collaboration with Bayer to advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies
|
|
|
|
|
|
|
|
|